Longevity research believes itself with crypto through Aubrai, a decentralized science (Desci) And agent AI was launched this week on the basis as part of the organic protocol.
Decentralized science, or DESCI, uses blockchain and DAOs to directly finance experiences, assign credit transparent and transform research results into token active ingredients that allow laboratories to maintain themselves beyond philanthropy and traditional capital markets.
The Token Aubrai, launched on LEPAD of Bio Protocol, makes permanent holders of permanent intervening in the results of the agent’s research, with governance rights on financing decisions and a share of income from the discovery marketed
Built by Vitadao and Bio Protocol with Aubrey de Gray’s Lev Foundation, Aubrai aims to fill the “Death Valley”, where the discoveries on a long horizon end while the retirement of the capital markets and the laboratories depend on philanthropy.
De Gray is a biomedical gerontologist better known for his research of pioneer longevity through his negligible senescence strategies designed (Sense) Framework and to recommend that aging can be treated as a curable condition.
“The consequences of traditional funding are a chronic funding gap, excessive dependence on philanthropy, and a” death valley “between discovery and clinic,” said from Gray to Coindesk in an interview.
“This is why we defend alternative mechanisms – DAOs, venture capital funds focused on longevity and desci platforms – which can tolerate long horizons, align incentives around societal advantages and the risk of a source of crowd,” said Gray.
Aubrai’s approach combines unpublished laboratory data from De Gray with Onchain’s incentives. By relying on unpublished laboratory data from De Gray, Aubrai has access to exclusive ideas beyond public literature, giving the agent an advantage of the generation of hypotheses of new and relevant trade in the science of longevity.
The agent ingests experiences in a graph of knowledge, generates hypotheses and transports them to Token-Holder votes for funding.
“We already see the agent formulating new intriguing hypotheses and recommending the next steps,” said Gray. “It is the combination of the Intelligence of Origin of AI and the expert human intelligence which has the potential to considerably accelerate the breakthrough in the fight against aging.”
Once the experiences have been validated, the discoveries are struck in IP tokens which can be authorized to pharmaceutical or biotechnological companies, with revenues that return to researchers and contributors.
The system is already used in The rejuvenation of the robust mouse of de Gray (RMR2) studyOne of the greatest experiences of mouse life ever attempted. Aubrai suggested methodological adjustments and reported dosage warnings that researchers had only discovered after weeks of manual review.
“Having the agent at our disposal has been a transformer for our planning pipeline,” said Gray, noting that RMR2 implies nearly a dozen that overlap. “He identified points of consideration that we had not yet encountered by literature, and he was proactive to suggest means to bypass the planned limitations.”
For Paul Kohlhaas, founder of Bio Protocol, Aubrai represents a turning point in the way science can be organized and funded.
“Just as Sublack gave writers the opportunity to monetize the inherited external media, the organic infrastructure can transform scientists into the next great economy of the creator,” he said.
Desci will face challenges
While projects like Aubrai and the organic protocol show that the potential of cryptographic capital beyond the same, tokenized intellectual property is likely to attract a regulatory examination and established pharmaceutical companies can hesitate to adopt discoveries born of decentralized collectives.
However, for an area such as longevity, where breakthroughs often die in space between the first results and human tests due to a disinterested capital market, Aubrai offers an alternative route.
If he succeeds, he could demonstrate the potential of the blockchain to make more than simply pump the next same. It could provide the infrastructure to accelerate research itself, pushing the field of longevity closer to therapies that extend human health.
This would also point out that decentralized science can function as a viable market alternative to rooted financing structures which have long limited biomedical innovation.
